The 18th World Bispecific Summit 2027 focuses on bispecific and multispecific antibody development, advancing next-generation T-cell engagers, and optimizing therapeutic design, safety, and clinical translation in oncology and immunology.
Key topics
Next-generation bispecific and multispecific therapeutic development trends
T-cell engager strategies for cancer and autoimmune disease treatment
Molecular design and rational target pairing for improved therapeutic windows
AI-guided drug design and multispecific antibody engineering approaches
Solid tumor targeting strategies including TCE potency and safety optimization
CMC development, formulation, and FDA-approved bispecific learnings
Biologics developability, stability, and downstream process optimization
Novel immuno-oncology modalities and masked multispecific antibody approaches
Co-stimulatory and conditionally active T-cell engager design strategies
Clinical translation using QSP modeling and biomarker-driven patient selection
Mechanistic modelling for dose selection and therapeutic optimization
Who should attend
Biopharmaceutical scientists and drug development researchers
Oncology and immunology clinical researchers
CMC and formulation development specialists
Antibody engineering and protein design experts
Translational medicine and clinical development professionals
Pharmaceutical R&D leaders in biologics innovation
